# Aging Interventions Evidence Hierarchy: Comprehensive Synthesis
## Evidence-Based Ranking of Longevity Therapies with Clinical Protocols

**Analysis Date**: November 8, 2025
**Research Scope**: 8 comprehensive intervention reports synthesized
**Evidence Sources**: 600+ clinical trials, animal studies, mechanistic research
**Purpose**: Actionable protocols with evidence grading for practical implementation

---

## Executive Summary

This synthesis ranks aging interventions by evidence strength, combining animal lifespan data, human clinical trials, mechanistic understanding, and safety profiles. Key finding: **Exercise has the strongest human evidence** for healthspan extension and mortality reduction, while pharmacological interventions show promise but lack definitive human lifespan data.

**Key Insights**:
- **Exercise** is the ONLY intervention with robust human evidence: 30-40% mortality reduction, multi-system benefits, minimal risk
- **Rapamycin** shows the most robust preclinical longevity data (10-15% lifespan extension in mice)
- **Metformin** has the largest human safety database but mixed efficacy signals
- **Senolytics** demonstrate cellular rejuvenation but clinical translation is early-stage
- **Reprogramming** represents the most revolutionary approach but faces significant safety hurdles
- **Combination therapies** (exercise + pharmacology) likely optimal for human healthspan extension

---

## Evidence Grading System

**Grade A**: Strong evidence for human healthspan/lifespan benefit
- Multiple large RCTs with consistent positive results
- Clear mechanistic understanding
- Established safety profile
- Regulatory approval or strong expert consensus

**Grade B**: Moderate evidence for benefit
- Some human RCTs showing benefits OR strong animal data + preliminary human data
- Plausible mechanisms
- Acceptable safety profile with appropriate monitoring
- Expert opinion divided or cautiously supportive

**Grade C**: Preliminary/mixed evidence
- Promising animal data but limited human trials OR inconsistent human results
- Mechanistic rationale present
- Safety concerns or unknown long-term effects
- Requires more research before broad recommendation

**Grade D**: Insufficient evidence or safety concerns
- Weak or contradictory evidence
- Unclear mechanisms or implausible claims
- Significant safety concerns
- Not recommended outside research settings

---

## GRADE A INTERVENTIONS

### 1. Exercise (Multi-Modal Training) ü•á **GOLD STANDARD**

**Evidence Summary**:
- **Most evidence-based non-pharmacological intervention** with extensive human validation
- **Mortality reduction**: 30-40% reduction in all-cause mortality (population studies)
- **Multi-system benefits**: Cardiovascular, metabolic, musculoskeletal, cognitive, immune, mental health
- **Safety**: Extremely safe when properly prescribed; minimal contraindications
- **Mechanism**: Comprehensive (AMPK, PGC-1Œ±, BDNF, autophagy, inflammation reduction, myokines)

**Lifespan/Healthspan Data**:
| Population | Intervention | Outcome | Evidence |
|-----------|-------------|---------|----------|
| Adults ‚â•60 | Aerobic training | VO‚ÇÇmax +16.3% | Meta-analysis (41 RCTs, n=2,102) |
| Lifelong exercisers | Chronic training | 50% slower VO‚ÇÇmax decline | Longitudinal studies |
| General population | Regular exercise | 30-40% ‚Üì mortality | Population cohorts |
| Elderly (‚â•65) | Resistance training | Muscle mass +1.1 kg | Meta-analysis (50+ RCTs) |
| Postmenopausal | HIIT + Resistance | Bone density +2.9%/year | LIFTMOR trial |
| Older adults (55-80) | Aerobic walking | Hippocampal volume +2% | Erickson 2011 RCT |
| Community elderly | Balance training | Fall rate -23% | Cochrane Review 2024 |

**Clinical Dosing Protocol**:

**Optimal Combined Training Program** (WHO/AHA/ACSM 2024):

**Aerobic Component**:
- **Frequency**: 5 days/week
- **Duration**: 150-300 min/week moderate-intensity OR 75-150 min/week vigorous-intensity
- **Intensity**:
  - Moderate: 50-70% HRmax (brisk walking, cycling)
  - Vigorous: 70-85% HRmax (jogging, running)
- **Modalities**: Walking, cycling, swimming, rowing, dancing

**Resistance Component**:
- **Frequency**: 2-3 days/week (full body)
- **Volume**: 2-4 sets √ó 8-12 reps per exercise
- **Intensity**: 60-80% 1RM
- **Exercises**: Multi-joint compounds (squats, deadlifts, chest press, rows, overhead press)
- **Rest**: 48-72 hours between sessions for same muscle groups

**HIIT Component** (optional, time-efficient):
- **Frequency**: 2-3 days/week
- **Protocol**: 4√ó4 Norwegian (4 min √ó 4 rounds at 85-95% HRmax, 3 min recovery)
- **Alternative**: 30-20-10 protocol, Tabata (advanced)
- **Safety**: Requires medical clearance for high-risk individuals

**Balance/Flexibility Component** (especially ‚â•65 years):
- **Frequency**: 2-3 days/week
- **Duration**: 20-30 min/session
- **Modalities**: Tai Chi, yoga, static stretching, balance exercises
- **Fall prevention**: Reduces fall rate 23%, fractures 16%

**Practical Weekly Template (Age 60+)**:
- **Monday**: Resistance training (45-60 min)
- **Tuesday**: Moderate aerobic + balance (45 min)
- **Wednesday**: Rest or light yoga
- **Thursday**: HIIT (30-40 min total including warm-up)
- **Friday**: Resistance training (45-60 min)
- **Saturday**: Longer aerobic session (45-60 min)
- **Sunday**: Rest or active recovery

**Molecular Mechanisms**:

**AMPK Activation**:
- Energy deficit ‚Üí AMPK activation ‚Üí mitochondrial biogenesis (+25-40%), autophagy (2-3√ó), metabolic flexibility
- Reverses age-related AMPK decline

**PGC-1Œ± Upregulation**:
- Exercise increases PGC-1Œ± 5-10√ó ‚Üí mitochondrial biogenesis
- Antioxidant defense ‚Üë, mitochondrial fusion proteins ‚Üë
- Restores mitochondrial quality (fewer damaged mitochondria)

**BDNF Increase**:
- Acute: +20-40% serum BDNF post-exercise
- Chronic: Baseline +15-30% after training
- Hippocampal volume +2% (Erickson 2011, n=120, age 55-80)
- Mechanism: Irisin (myokine) crosses BBB ‚Üí BDNF transcription ‚Üë

**Myokine Secretion**:
- IL-6 (transient spike, anti-inflammatory downstream)
- Irisin (adipose browning, BDNF induction)
- Myostatin ‚Üì (removes brake on muscle growth)
- Systemic anti-inflammatory effects

**Autophagy Enhancement**:
- 2-3√ó increase in autophagy markers during/post-exercise
- Mitophagy: Damaged mitochondria selectively removed
- Protein quality control, cellular rejuvenation

**Inflammation Reduction**:
- CRP ‚Üì 20-40%, IL-6 ‚Üì 20-30%, TNF-Œ± ‚Üì 15-25%
- Adiponectin ‚Üë 20-40%
- Mechanisms: Visceral fat loss, macrophage polarization (M1‚ÜíM2), myokine effects

**Safety Profile**:

**Advantages**:
- No significant adverse effects when properly prescribed
- Multi-system benefits without pharmacological side effects
- Improves quality of life, functional independence
- Sustainable lifelong intervention
- Low cost

**Precautions**:
- **Medical clearance**: Required for sedentary with cardiovascular risk factors before HIIT
- **Progressive overload**: Increase volume 10% per week (avoid overtraining/injury)
- **Proper form**: Essential for resistance training (injury prevention)
- **Recovery**: Adequate rest between sessions (48-72 hours for resistance)
- **Modifications**: Lower-impact for joint issues (cycling, swimming vs. running)

**Contraindications** (relative):
- Unstable angina or recent MI (<6 months) - defer HIIT
- Uncontrolled hypertension (>180/110) - defer vigorous exercise
- Severe aortic stenosis - exercise with caution
- Acute heart failure - stabilize first
- Uncontrolled arrhythmias - medical management first

**Monitoring Protocol**:
- **Baseline**: Exercise stress test if high-risk (optional for moderate-intensity)
- **Self-monitoring**: Heart rate monitor, RPE scale (Rate of Perceived Exertion)
- **Functional assessments**: Grip strength, gait speed, chair stand, balance tests (3-6 month intervals)
- **Overtraining signs**: Elevated resting HR, reduced HRV, persistent fatigue, performance decline

**Synergistic Combinations**:
1. **Exercise + Mediterranean Diet**: MedEx-UK trial (2024) showed synergistic cardiovascular and cognitive benefits
2. **Exercise + Resistance Training + Protein (1.2-1.6 g/kg/day)**: Optimal for sarcopenia prevention (+87% greater muscle mass gain)
3. **Exercise + Rapamycin**: Exercise provides anabolic stimulus while rapamycin provides catabolic benefits; may be complementary
4. **Exercise + Metformin**: ‚ö†Ô∏è Caution - metformin may blunt mitochondrial adaptations to exercise; consider lower metformin dose if optimizing fitness

**Clinical Trial Evidence**: ‚úÖ **Hundreds of RCTs, consistent positive results**
- **VO‚ÇÇmax**: Meta-analysis (41 RCTs, n=2,102, ‚â•60 years) ‚Üí +16.3% improvement
- **Muscle mass**: Meta-analysis (50+ RCTs) ‚Üí +1.1 kg gain (6-12 months)
- **Bone density**: LIFTMOR trial ‚Üí +2.9% lumbar spine per year
- **Cognition**: Meta-analysis (50+ RCTs, n=5,000+) ‚Üí moderate improvement (d=0.3-0.5)
- **Inflammation**: Meta-analysis (40+ RCTs) ‚Üí CRP -20-40%, IL-6 -20-30%
- **Blood pressure**: Meta-analysis (50+ RCTs, n=5,000+) ‚Üí SBP -5 to -10 mmHg
- **Insulin sensitivity**: Meta-analysis ‚Üí HOMA-IR -20 to -40%
- **Falls**: Cochrane Review 2024 ‚Üí 23% reduction in fall rate

**Dose-Response Relationship**:
- **Minimum**: 150 min/week moderate-intensity ‚Üí 20-25% mortality reduction
- **Optimal**: 300 min/week moderate-intensity ‚Üí 30-35% mortality reduction
- **Diminishing returns**: >450-600 min/week (plateau, increased injury risk)
- **Intensity**: Each 1 MET (3.5 mL/kg/min) increase ‚Üí 10-15% mortality reduction

**Special Populations**:
- **Late-life initiation**: Effective even when started at 60-70 years
- **Frailty**: 40-60% reduction in frailty risk with regular exercise
- **Reversibility**: Can reverse age-related decline in endothelial function, muscle mass, cognitive function
- **Sex differences**: Benefits both sexes equally; females may have greater cognitive benefits

**Evidence Grade**: **A** (strongest human evidence of any intervention, multi-system benefits, extensive safety data, expert consensus)

---

## GRADE B INTERVENTIONS

### 2. Rapamycin (mTOR Inhibition) ü•á **STRONGEST PRECLINICAL EVIDENCE**

**Evidence Summary**:
- **Lifespan extension**: 10-15% median, consistently across nearly all mouse studies
- **Late-life efficacy**: Effective even when started at 600 days (‚âà60 human years)
- **Mechanism**: mTOR inhibition ‚Üí autophagy, reduced protein synthesis, improved mitochondrial function
- **Human trials**: PEARL (2025), TRIAD (dogs), multiple disease-specific trials ongoing

**Lifespan/Healthspan Data**:
| Model | Intervention | Median Extension | Healthspan |
|-------|-------------|------------------|------------|
| Mice (‚ôÄ) | Continuous 42 ppm | +15% | Improved frailty, function |
| Mice (‚ôÇ) | Continuous 42 ppm | +11% | Improved frailty, function |
| Mice (old) | Started 124 weeks | +109% remaining | Reduced frailty |
| Dogs | 1 year treatment | Ongoing (TRIAD) | Cardiac improvement |
| Humans | PEARL 48 weeks | No lifespan data | Modest biomarker changes |

**Clinical Dosing Protocol**:

**Standard Longevity Protocol**:
- **Drug**: Rapamycin (sirolimus, generic)
- **Dose**: 5-7 mg once weekly (start 3-5 mg, titrate based on levels)
- **Route**: Oral with meal
- **Alternative**: 10-15 mg every 2 weeks (biweekly)
- **Duration**: Chronic (continuous monitoring required)

**Intermittent vs. Continuous**:
- **Intermittent preferred**: Preserves mTORC2, reduces metabolic side effects
- **Females**: Continuous slightly superior for lifespan (+15% vs +8%)
- **Males**: Intermittent equivalent to continuous (+9-11% both)

**Safety Profile**:

*Common Side Effects* (dose-dependent):
- **Mouth ulcers** (20-40%): Prevent with dexamethasone mouthwash 4√ó/day
- **Glucose intolerance** (30-50%): Reversible, intermittent dosing reduces; combine with metformin
- **Hyperlipidemia** (20-30%): Monitor, statins if needed
- **GI symptoms** (10-20%): Mild nausea, diarrhea

*Serious Concerns*:
- **Immunosuppression** (high-dose): At longevity doses, may actually improve immunity in elderly (paradox)
- **Wound healing** (impaired): Hold 1-2 weeks before elective surgery
- **Male fertility** (reduced): Reversible within 2 months of cessation
- **Cancer risk** (theoretical): Preclinical data suggest protection, not promotion

**Monitoring Protocol**:
- **Baseline**: CBC, CMP, lipids, HbA1c, rapamycin level
- **Week 2-4**: Rapamycin level (trough <1 ng/mL, peak >10 ng/mL)
- **Month 3**: CBC, glucose, HbA1c, lipids, rapamycin level
- **Every 3-6 months**: Above labs
- **Annually**: Comprehensive assessment

**Contraindications**:
- Active infection
- Severe renal impairment (eGFR <30)
- Pregnancy/lactation
- Upcoming surgery (hold 2 weeks prior)
- Uncontrolled diabetes

**Drug Interactions**:
- **CYP3A4 inhibitors**: Ketoconazole, grapefruit (increase levels)
- **CYP3A4 inducers**: Rifampin (decrease levels)
- Monitor levels closely with any drug changes

**Synergistic Combinations**:
1. **Rapamycin + Metformin**: Counteracts glucose effects, sex-neutral lifespan benefits
2. **Rapamycin + Resveratrol**: Synergistic autophagy induction
3. **Triple (Rapa + Met + Resv)**: Maximum autophagy, improved metabolic profile

**Clinical Trial Status**: ‚è≥ Ongoing
- REACH (Alzheimer's, UT San Antonio)
- EVERLAST (insulin resistance, U Wisconsin)
- TRIAD (dogs, lifespan endpoint, Dog Aging Project)

**Evidence Grade**: **B** (strong animal data, emerging human safety data, no human lifespan data)

---

### 3. Metformin (AMPK Activation)

**Evidence Summary**:
- **Observational**: Type 2 diabetics on metformin may outlive non-diabetic controls (controversial)
- **Animal data**: Mirrors dietary restriction in some models but meta-analysis shows NO significant lifespan extension in vertebrates
- **Mechanism**: AMPK activation, mild complex I inhibition, mitochondrial effects, microbiome modulation
- **Human trials**: TAME trial (3,000 participants, 6 years) - results expected 2027-2028

**Lifespan/Healthspan Data**:
| Model | Intervention | Median Extension | Healthspan |
|-------|-------------|------------------|------------|
| Mice | Various studies | 0% (meta-analysis 2024) | Mixed |
| Humans | Cardiff study | +15% (confounded) | No data |
| Humans | TAME trial | Pending (2027) | Pending |

**Critical Finding**: 2024 meta-analysis (911 effect sizes, 167 papers, 8 vertebrate species) found **metformin does NOT extend lifespan** while rapamycin does. This contradicts earlier enthusiasm.

**Clinical Dosing Protocol**:

**Standard Protocol**:
- **Drug**: Metformin extended-release (generic)
- **Starting dose**: 500 mg once daily with dinner
- **Titration**: Increase 500 mg weekly to target
- **Target dose**: 1,500-2,000 mg once daily
- **Maximum**: 2,000 mg/day (ER formulation)
- **Timing**: With largest meal (reduces GI effects)

**TAME Trial Protocol** (for reference):
- **Dose**: 1,500 mg/day extended-release
- **Duration**: 6 years
- **Population**: 3,000 adults age 65-79 without diabetes
- **Endpoint**: Composite (CV events, cancer, cognitive impairment, mortality)

**Safety Profile**:

*Common Side Effects*:
- **GI symptoms** (20-30%): Diarrhea, nausea, bloating (usually transient)
- **B12 deficiency** (10-30% long-term): Requires supplementation (1,000-2,000 mcg/day)
- **Lactic acidosis** (very rare, <10/100,000): In renal impairment, severe illness

*Contraindications*:
- eGFR <30 mL/min/1.73m¬≤ (absolute)
- eGFR 30-45 (caution, do not initiate)
- Severe liver disease
- Alcohol abuse
- Acute illness (hold temporarily)

**Monitoring Protocol**:
- **Baseline**: Renal function (eGFR), B12, CBC
- **Every 6-12 months**: eGFR, B12, CBC
- **B12 supplementation**: Mandatory (1,000 mcg/day minimum)

**Exercise Interaction** ‚ö†Ô∏è:
- **Concern**: May blunt mitochondrial adaptations to exercise (2019 study, Aging Cell)
- **Effect**: Reduced VO2 max improvements, less mitochondrial biogenesis
- **Recommendation**: Consider lower dose or avoid if optimizing athletic performance

**Synergistic Combinations**:
1. **Metformin + Rapamycin**: Minimal overlap, additive benefits (see Rapamycin section)
2. **Metformin + Resveratrol**: SIRT1 (resv) + AMPK (met) complementary pathways
3. **Metformin + NAD+ boosters**: Synergistic mitochondrial and metabolic effects

**Clinical Trial Status**: ‚è≥ **TAME trial results 2027-2028 will be definitive**

**Evidence Grade**: **B** (extensive human safety data, mixed efficacy signals, major trial pending)

---

### 4. Senolytics (Dasatinib + Quercetin)

**Evidence Summary**:
- **Mechanism**: Selective elimination of senescent cells by transiently disabling pro-survival pathways (SCAPs)
- **Preclinical**: Robust benefits in aged and progeroid mice (healthspan, some lifespan)
- **Human trials**: 30+ trials completed or ongoing; first-in-human showed senescent cell reduction
- **Dosing**: Intermittent "hit-and-run" (3 days every 2-4 weeks)

**Lifespan/Healthspan Data**:
| Model | Intervention | Median Extension | Healthspan |
|-------|-------------|------------------|------------|
| Progeroid mice | D+Q intermittent | +35% vs untreated | Reversed frailty |
| Aged mice | D+Q intermittent | +36% post-treatment survival | Improved function |
| Humans (DKD) | D+Q 3 days | No lifespan data | Reduced senescence markers (11 days) |
| Humans (IPF) | D+Q 3 weeks | No lifespan data | Improved 6MWD, gait speed |

**Clinical Dosing Protocol**:

**Standard D+Q Protocol** (most studied):
- **Dasatinib**: 100 mg/day
- **Quercetin**: 1,000-1,250 mg/day
- **Schedule**: 3 consecutive days, then off
- **Frequency**: Every 2-4 weeks
- **Duration**: 6 cycles (12 weeks typical)

**Cycle Options**:
1. **Weekly**: 3 days on, 4 days off, repeat 3-4 times
2. **Biweekly**: 2-3 days on, 11-12 days off, repeat 6 times
3. **Monthly**: 3 days on, 25 days off (less studied)

**Alternative: Fisetin Monotherapy**:
- **Dose**: 20 mg/kg body weight (1,400 mg for 70 kg person)
- **Schedule**: 2 consecutive days per month
- **Duration**: 3-6 cycles
- **Note**: Lower bioavailability, requires high doses; liposomal formulations improve absorption

**OSK Preference**: Most clinical programs using OSK (Oct4, Sox2, Klf4) without c-Myc for safety

**Safety Profile**:

*Common (Mild-Moderate)*:
- **GI discomfort** (30-40%): Transient nausea, diarrhea
- **Skin irritation/bruising** (variable): Dasatinib antiplatelet effects
- **Headache** (10-20%): Usually mild

*Rare but Monitor*:
- **Hypotension** (rare): Quercetin vasodilator effects
- **Bleeding** (rare): Dasatinib platelet effects

*Long-term Concerns*:
- **Tissue repair impairment**: Continuous dosing impairs wound healing; intermittent dosing safe
- **Beneficial senescence**: Senescent cells aid wound healing; "hit-and-run" preserves this

**Monitoring Protocol**:
- **Baseline**: CBC, CMP, BP
- **During treatment**: Monitor for bleeding, GI symptoms
- **Post-cycle**: CBC (if on anticoagulants)
- **No specific long-term monitoring** (intermittent use)

**Contraindications**:
- Active bleeding disorder
- Thrombocytopenia (<100k platelets)
- Concurrent anticoagulation (caution, not absolute)
- Planned surgery (hold 1 week prior)

**Clinical Trial Status**: üöÄ **Multiple active trials**
- **NCT02848131** (DKD): ‚úÖ Completed - First human proof-of-concept
- **NCT04063124** (Alzheimer's - SToMP-AD): ‚úÖ Completed - Feasibility shown
- **NCT04313634** (Osteoporosis): ‚úÖ Completed 2024 - Mixed results (responders with high senescence burden)
- **STAMINA** (MCI + slow gait): ‚úÖ Published Feb 2025 - Feasible, hints at benefits
- **Fisetin for frailty** (NCT03325322): ‚è≥ Ongoing
- **Long COVID/ME/CFS**: ‚è≥ Multiple trials ongoing

**Evidence Grade**: **B** (strong preclinical data, human proof-of-concept established, efficacy trials ongoing)

---

## GRADE C INTERVENTIONS

### 5. Epigenetic Reprogramming (OSKM/OSK Factors)

**Evidence Summary**:
- **Mechanism**: Transient expression of Yamanaka factors resets epigenetic age without losing cell identity
- **Preclinical**: Vision restoration (mice, NHP), cognitive improvement (aged mice), 109% lifespan extension in very old mice (124 weeks)
- **Human trials**: First clinical trials 2026 (Life Biosciences ER-100 for glaucoma/NAION)
- **Revolutionary but early**: Most ambitious aging intervention, significant safety hurdles

**Lifespan/Healthspan Data**:
| Model | Intervention | Median Extension | Healthspan |
|-------|-------------|------------------|------------|
| Progeroid mice | Cyclic OSKM | Rescued early death | Rescued healthspan |
| Aged mice (124w) | AAV9-OSK systemic | +109% remaining | Reduced frailty |
| Aged mice | Cyclic OSKM brain | Not measured | Memory improvement |
| Mice/NHP | AAV2-OSK eye | Not measured | Vision restoration |

**Clinical Dosing Protocol**: **NOT YET AVAILABLE FOR CLINICAL USE**

**Anticipated First Protocols** (based on preclinical and pending trials):

**Life Biosciences ER-100** (Glaucoma/NAION, 2026):
- **Vector**: AAV2-OSK (Oct4, Sox2, Klf4)
- **Route**: Intravitreal injection (single dose)
- **Target**: Retinal ganglion cells
- **Safety**: 21-month studies show no tumors, dedifferentiation

**YouthBio YB002** (Alzheimer's, ~2028):
- **Vector**: AAV-OSKM (includes c-Myc, transient)
- **Route**: Stereotactic brain injection (single dose)
- **FDA milestone**: Positive INTERACT meeting (Sept 2025)
- **Status**: IND-enabling studies ongoing

**Turn.bio TRN-001** (Skin, 2026):
- **Technology**: Proprietary (topical/intradermal likely)
- **Route**: Local skin application
- **Status**: IND-enabling studies

**Safety Profile**: ‚ö†Ô∏è **SIGNIFICANT CONCERNS**

*Major Risks*:
- **Teratoma formation**: OSKM can induce pluripotency ‚Üí tumors (continuous high-dose exposure)
  - Mitigation: OSK without c-Myc, transient expression, intermittent dosing
  - Evidence: 21-month studies with short-pulse OSK show no tumors
- **Cancer risk**: c-Myc is proto-oncogene
  - Mitigation: Remove c-Myc (OSK or OS combinations), short exposure
- **Loss of cellular identity**: Excessive reprogramming erases cell type
  - Mitigation: Tissue-specific promoters, cyclic dosing (2 days on, 5 off)
  - Evidence: Organ-specific responses (liver minimal, kidney some dedifferentiation)
- **Unknown long-term effects**: No decades-long human data

*Clinical Approach*:
- Start with **local delivery** (eye, skin) before systemic
- **Intermittent pulsing**: 2-7 day exposure cycles
- **Extensive monitoring**: Tumor markers, imaging, histology
- **Long-term follow-up**: 12+ months minimum

**Monitoring Protocol** (anticipated):
- **Baseline**: Full oncology workup, tumor markers, imaging
- **Post-treatment**: Monthly imaging (first 6 months), tumor markers
- **Long-term**: Annual comprehensive for 5+ years
- **Biomarkers**: Epigenetic clocks, senescence markers, lineage markers

**Clinical Trial Status**: üöÄ **Clinical translation 2026-2028**
- **Life Biosciences ER-100**: Q1 2026 Phase 1 (most advanced)
- **YouthBio YB002**: ~2028 Phase 1 (FDA feedback positive)
- **Turn.bio TRN-001**: 2026 target
- **Altos Labs**: Ex vivo organ rejuvenation (timeline unclear)

**Evidence Grade**: **C** (revolutionary preclinical data, first clinical trials imminent, significant safety uncertainties)

---

### 6. Polyphenols (Resveratrol, Curcumin, EGCG)

**Evidence Summary**:
- **Mechanisms**: Multiple (SIRT1 activation, AMPK, NRF2, autophagy, anti-inflammatory, antioxidant)
- **Preclinical**: Lifespan extension in lower organisms (yeast, worms, flies); mixed in mice
- **Bioavailability crisis**: Most have <5% oral absorption (curcumin ~1%, resveratrol ~0.5%)
- **Human trials**: Modest benefits, highly variable; epidemiological data stronger than intervention trials

**Lifespan/Healthspan Data**:
| Compound | Model | Extension | Human Efficacy |
|----------|-------|-----------|----------------|
| Resveratrol | Yeast | +70% | Minimal (meta-analysis) |
| Resveratrol | Mice (HFD) | Improved survival | Glucose -2.4 mg/dL (barely significant) |
| Resveratrol | Mice (standard) | 0% | Endothelial +1-2% FMD |
| Curcumin | Various | Varies | Arthritis pain relief (strong) |
| EGCG | C. elegans | +14-29% | Weight -1.3 kg (meta-analysis) |

**Clinical Dosing Protocols**:

**Resveratrol**:
- **Standard**: 150-500 mg/day trans-resveratrol
- **High-dose trials**: 1-5 g/day (safe but expensive)
- **Enhanced formulation**: Micronized or liposomal (3-5√ó bioavailability)
- **Timing**: With fat-containing meal
- **Realistic expectations**: Modest effects; dietary sources (red wine 2-8 mg/glass) insufficient

**Curcumin**:
- **Standard (with piperine)**: 1-3 g/day curcumin + 20 mg piperine
- **Enhanced bioavailability** (preferred):
  - BCM-95¬Æ: 500-1,000 mg/day
  - Meriva¬Æ (phytosome): 1,000 mg 2√ó/day (arthritis)
  - Longvida¬Æ: 400 mg/day (brain-targeted)
  - NovaSOL¬Æ: 500 mg/day (185√ó bioavailability, most potent)
- **Timing**: With meals containing fat
- **Condition-specific**: Arthritis (Meriva), cognitive (Longvida), general (NovaSOL)

**EGCG (Green Tea)**:
- **Dietary**: 3-5 cups green tea/day (300-600 mg EGCG)
- **Supplement**: 400-800 mg/day EGCG extract
- **Matcha**: 1-2 servings/day (higher concentration)
- **Timing**: Between meals (absorption) or with meals (tolerability)
- **Caution**: High doses (>800 mg/day) may cause liver enzyme elevation

**Safety Profile**:

*Resveratrol*:
- **Generally safe**: Up to 5 g/day in trials
- **Side effects**: GI upset at high doses (>1 g/day)
- **Interactions**: Anticoagulants (may potentiate), CYP450 substrates

*Curcumin*:
- **Generally safe**: Up to 12 g/day short-term
- **Side effects**: GI upset (rare), nausea (high doses)
- **Interactions**: Anticoagulants (caution), diabetes meds (monitor glucose)
- **Contraindications**: Gallstones, bleeding disorders, before surgery (hold 2 weeks)

*EGCG*:
- **Generally safe**: Up to 800 mg/day
- **Hepatotoxicity**: Rare at high doses (>800 mg/day on empty stomach)
- **Side effects**: Nausea, insomnia (caffeine in tea), constipation
- **Interactions**: Iron absorption (reduced), beta-lactam antibiotics (enhanced)

**Synergistic Combinations**:
- **Resveratrol + Quercetin**: May improve bioavailability
- **Curcumin + Piperine**: 20√ó bioavailability increase (standard)
- **Polyphenol stack**: Resv 250 mg + Curc 500 mg + EGCG 400 mg (theoretical synergy)

**Clinical Trial Status**: ‚úÖ Many completed, ongoing
- Resveratrol: Dozens of RCTs, consistently modest/mixed results
- Curcumin: Strong evidence for arthritis (meta-analyses), mixed for metabolic
- EGCG: Weight loss (~1.3 kg), metabolic benefits in meta-analyses

**Evidence Grade**: **C** (strong epidemiological data, modest intervention trial results, bioavailability limits clinical utility despite compelling mechanisms)

---

### 7. Peptides (Various)

**Evidence Summary**:
- **Diversity**: Growth factors (GH, IGF-1, FGF21), synthetic peptides (Epitalon, BPC-157), hormones (thymosin Œ±1)
- **Paradox**: GH/IGF-1 low = longevity (observational) yet replacement treats symptoms
- **Safety**: Variable; GH has significant side effects and cancer concerns
- **Availability**: Most not approved for aging; grey market for some

**Clinical Dosing Protocols** (limited applicability):

**NOT RECOMMENDED for general anti-aging use**:
- **Growth Hormone (rhGH)**: Major societies (Endocrine Society, AGS) do NOT recommend for healthy aging
  - Side effects: Fluid retention (20-40%), carpal tunnel (10-20%), insulin resistance (15-30%)
  - Cancer risk: Theoretical but concerning (IGF-1 promotes tumor growth)
  - Cost: $10,000-$30,000/year
- **Tesamorelin (GHRH agonist)**: More physiologic, reduces visceral fat, but expensive ($4,000-6,000/month) and effects reversible
- **Epitalon**: Unproven, no FDA approval, quality control issues, unknown long-term safety

**POTENTIALLY USEFUL (specific contexts)**:
- **Thymosin Œ±1**: Immune enhancement in immunocompromised; not approved in US; 1.6 mg SC 2-3√ó/week
  - Evidence: Strong for immune restoration, weak for healthy aging
- **Oxytocin**: Muscle regeneration, metabolic benefits; intranasal delivery; safety good but efficacy in aging untested
- **BDNF**: Cannot deliver to brain effectively; focus on lifestyle (exercise, diet) to increase endogenous production

**Safety Profile**: ‚ö†Ô∏è Variable, often concerning

**GH/IGF-1 Paradox**:
- **Resolution**: Pulsatile vs. chronic, dose-response curve, tissue-specific effects, evolutionary trade-off
- **Recommendation**: Replacement only for documented deficiency with medical supervision

**Synergistic Combinations**: Not well-studied; risk > benefit for most peptides in healthy aging

**Clinical Trial Status**: Variable
- **FGF21 analogs** (Efruxifermin): ‚è≥ Phase 2b/3 for NASH (impressive results), may extend to aging
- **GDF11**: Deeply controversial, no human trials yet, likely avoid
- **Most others**: Limited or no rigorous trials

**Evidence Grade**: **C to D** (compelling mechanisms for some, significant safety concerns, limited human aging data, most not recommended outside specific deficiency states)

---

## GRADE D INTERVENTIONS

### 8. Interventions NOT Currently Supported

**Insufficient Evidence or Significant Safety Concerns**:

1. **Epitalon** (Grade D):
   - Limited to one Russian research group
   - No independent replication
   - Mechanistic implausibility (telomerase activation)
   - Unknown long-term safety (cancer risk)
   - No FDA/EMA approval
   - **Recommendation**: Do NOT use

2. **GDF11** (Grade D):
   - Fundamental controversy unresolved
   - Mixed results on whether it increases or decreases with age
   - Risk of myostatin-like muscle inhibition
   - No human trials
   - **Recommendation**: Avoid; research ongoing

3. **Most "Anti-Aging Peptide Cocktails"** (Grade D):
   - Often combine multiple unproven peptides
   - Lack rigorous evidence
   - Unknown interactions
   - Safety not established
   - Often from grey market sources (quality concerns)
   - **Recommendation**: Avoid

4. **High-Dose Growth Hormone in Healthy Aging** (Grade D):
   - Not recommended by major scientific societies
   - Significant side effects outweigh modest body composition changes
   - No functional improvements
   - Cancer risk theoretical but concerning
   - **Recommendation**: Only for documented deficiency

---

## SYNERGISTIC COMBINATIONS: Evidence-Based Stacks

### Stack 0: **Exercise + Mediterranean Diet** ü•á **FOUNDATION STACK (Grade A)**

**Rationale**:
- **Both Grade A evidence** for human healthspan extension
- **Synergistic effects** demonstrated in MedEx-UK trial (2024)
- **Multi-system benefits**: Cardiovascular, metabolic, cognitive, musculoskeletal
- **No adverse effects**: Safe, sustainable, cost-effective
- **Most impactful combination** of any interventions

**Protocol**:
- **Exercise**: Combined training (see Exercise section for full protocol)
  - Aerobic: 150-300 min/week
  - Resistance: 2-3 days/week
  - Balance: 2-3 days/week (‚â•65 years)
- **Mediterranean Diet**:
  - Extra virgin olive oil (primary fat source)
  - Fish 2-3√ó/week, legumes, nuts, whole grains
  - Abundant vegetables and fruits
  - Moderate red wine (optional, 1-2 glasses/day)
  - Limit red meat, processed foods, refined sugars
  - Rich in polyphenols naturally (no supplementation needed)

**Expected Benefits**:
- **Mortality**: 30-40% reduction (exercise) + additional cardiovascular protection (diet)
- **Cognitive**: Synergistic protection against dementia (MedEx-UK trial)
- **Cardiovascular**: Superior endothelial function, arterial compliance
- **Metabolic**: Enhanced insulin sensitivity, reduced inflammation
- **Multi-system**: Benefits across all organ systems

**Evidence**: Grade A (MedEx-UK trial 2024 showed synergistic cardiovascular and cognitive benefits beyond either alone)

**Cost**: Low ($200-500/month for Mediterranean diet ingredients, exercise free)

---

### Stack 1: **Exercise + Rapamycin + Metformin** ‚≠ê **COMPREHENSIVE APPROACH**

**Rationale**:
- **Exercise (anabolic)** + **Rapamycin (catabolic)** may be complementary
- **Metformin** counteracts rapamycin glucose effects, adds AMPK activation
- **Three pathways**: Exercise (AMPK/PGC-1Œ±/BDNF) + mTOR‚Üì (rapa) + AMPK‚Üë (met)
- **Animal data**: Combination shows benefits in both sexes
- **Safety**: Well-tolerated when combined

**Protocol**:
- **Exercise**: Combined training (full protocol) - NON-NEGOTIABLE
- **Rapamycin**: 5-7 mg weekly
- **Metformin**: 1,500 mg ER daily (lower dose acceptable if exercise optimized)
  - ‚ö†Ô∏è Note: Metformin may blunt mitochondrial adaptations to exercise; consider 1,000 mg if prioritizing fitness gains

**Expected Benefits**:
- **Exercise**: Multi-system benefits (cardiovascular, cognitive, musculoskeletal)
- **Autophagy**: Triple induction (exercise + rapa + met)
- **Metabolic**: Glucose tolerance preserved (metformin counteracts rapamycin)
- **Longevity pathways**: AMPK, mTOR, autophagy, mitochondrial function all optimized

**Evidence**: Grade B (exercise Grade A, pharmacology combination Grade B)

**Cost**: $2,000-4,000/year (medication + monitoring) + time for exercise

---

### Stack 2: **Rapamycin + Metformin** (Pharmacology Only)

**Rationale**:
- **Complementary pathways**: mTOR‚Üì (rapa) + AMPK‚Üë (met)
- **Metformin counteracts** rapamycin-induced glucose intolerance
- **Lifespan data**: Combination shows equal benefit in both sexes (rapa alone shows sex differences)
- **Safety**: Both well-studied individually; combination used in cancer trials

**Protocol**:
- Rapamycin: 5-7 mg weekly
- Metformin: 1,500-2,000 mg ER daily
- Monitoring: Combine protocols from each

**Expected Benefits**:
- Metabolic optimization
- Enhanced autophagy
- Reduced sex-specific variability
- Glucose tolerance improved vs. rapamycin alone

**Evidence**: Grade B (animal data strong, human combination limited but safe)

---

### Stack 3: **Rapamycin + Metformin + Resveratrol** üî¨ TRIPLE AUTOPHAGY

**Rationale**:
- **Three autophagy pathways**: mTOR (rapa), AMPK (met), SIRT1 (resv)
- **Synergistic**: All converge on autophagy via different mechanisms
- **Preclinical**: Combination promotes autophagy to mitigate NASH in animal models

**Protocol**:
- Rapamycin: 5-7 mg weekly
- Metformin: 1,500 mg ER daily
- Resveratrol: 250-500 mg/day (micronized or liposomal)

**Expected Benefits**:
- Maximum autophagy induction (cellular cleanup)
- Complementary metabolic effects
- Anti-inflammatory synergy
- Mitochondrial function

**Evidence**: Grade C (strong mechanistic rationale, limited human combination data)

---

### Stack 4: **Senolytics (Intermittent) + Continuous Interventions**

**Rationale**:
- **Senolytics** clear senescent cells periodically
- **Continuous interventions** (rapa, met) prevent accumulation

**Protocol**:
- Dasatinib 100 mg + Quercetin 1,250 mg: 3 days every 3-4 months
- Rapamycin 5-7 mg weekly (continuous)
- Metformin 1,500 mg daily (continuous)

**Timing**:
- No direct interaction; can take concurrently
- May synergize (rapamycin reduces SASP, senolytics clear senescent cells)

**Expected Benefits**:
- Periodic senescent cell clearance
- Ongoing senescence prevention
- Complementary mechanisms

**Evidence**: Grade C (logical combination, no direct human testing)

---

### Stack 5: **Polyphenol Cocktail** (Dietary/Supplemental)

**Rationale**:
- Multiple complementary mechanisms
- Whole foods show synergy (entourage effect)
- Low risk, dietary sources available

**Protocol**:
- Resveratrol: 250 mg/day (micronized)
- Curcumin: 500 mg/day (enhanced formulation like NovaSOL¬Æ)
- EGCG: 400 mg/day (or 3 cups green tea)
- Quercetin: 500 mg/day (if not using for senolytics)

**Dietary Alternative**:
- Mediterranean diet rich in polyphenols
- 3-5 cups green tea/day
- Turmeric in cooking with black pepper
- Red wine (1-2 glasses/day, optional)
- Berries, dark chocolate, extra virgin olive oil

**Expected Benefits**:
- Anti-inflammatory
- Antioxidant
- Multiple aging pathway modulation
- Low risk, dietary integration possible

**Evidence**: Grade C (strong epidemiological, modest intervention trial data)

---

## MONITORING AND SAFETY: Cross-Intervention Considerations

### Comprehensive Monitoring Panel

**Baseline (Before Starting Any Intervention)**:
- Complete metabolic panel (glucose, kidney function, liver function, electrolytes)
- CBC with differential
- Lipid panel (TC, LDL, HDL, TG)
- HbA1c, fasting insulin
- hs-CRP (inflammation)
- Vitamin B12 (if metformin)
- Rapamycin level (if rapamycin)
- Testosterone (males if rapamycin)
- Blood pressure, weight, BMI

**Ongoing Monitoring (Every 3-6 Months)**:
- Labs above (tailored to intervention)
- Functional assessments: Grip strength, gait speed, cognitive screening
- Side effect review
- Adherence check

**Annual Comprehensive**:
- All baseline labs
- Physical examination
- Functional assessments
- Risk-benefit reassessment
- Protocol adjustments

---

## PRACTICAL RECOMMENDATIONS BY AGE AND HEALTH STATUS

### Age 40-50 (Healthy, Preventive Focus)

**Tier 1 (NON-NEGOTIABLE FOUNDATION)**:
- ‚úÖ **EXERCISE** (Grade A): Combined aerobic + resistance training
  - **Aerobic**: 150-300 min/week moderate-intensity (brisk walking, cycling)
  - **Resistance**: 2-3 days/week full-body strength training
  - **HIIT**: 1-2 days/week (optional, time-efficient)
  - **Impact**: 30-40% mortality reduction, multi-system benefits
- ‚úÖ **Mediterranean Diet**: Rich in polyphenols, healthy fats, whole foods
- ‚úÖ **Sleep**: 7-9 hours/night (critical for recovery, longevity)
- ‚úÖ **Stress management**: Meditation, mindfulness, social connection

**Tier 2 (Consider After 1-2 Years)**:
- üü° **Metformin**: 1,000-1,500 mg ER daily (if prediabetic or metabolic syndrome)
- üü° **Polyphenol supplementation**: Enhanced formulations if dietary intake insufficient

**NOT Recommended**:
- ‚ùå Rapamycin (too early, risk > benefit at this age without disease)
- ‚ùå Senolytics (minimal senescence burden at this age)
- ‚ùå GH or peptides (no deficiency)

---

### Age 50-65 (Middle Age, Optimization Focus)

**Tier 1 (ESSENTIAL - Strongly Prioritize)**:
- ‚úÖ **EXERCISE** (Grade A): Intensify or maintain consistency
  - **Aerobic**: 150-300 min/week (mix moderate + vigorous)
  - **Resistance**: 2-3 days/week (crucial for sarcopenia prevention)
  - **HIIT**: 2 days/week (mitochondrial health, time-efficient)
  - **Balance**: Add 1-2 days/week (fall prevention starts now)
  - **Note**: Exercise more critical at this age to offset decline
- ‚úÖ **Protein intake**: Increase to 1.2-1.6 g/kg/day (combat anabolic resistance)
- ‚úÖ **Mediterranean Diet**: Anti-inflammatory, cardiovascular protection
- ‚úÖ **Metformin**: 1,500-2,000 mg ER daily (if metabolic risk factors present)

**Tier 2 (Consider After Risk-Benefit Analysis)**:
- üü° **Rapamycin**: 5-7 mg weekly (if risk-tolerant, under medical supervision)
- üü° **Exercise + Metformin + Rapamycin**: Optimal window for triple approach
- üü° **Senolytics**: 3-day pulse every 3-6 months (if inflammatory conditions, arthritis)
- üü° **Polyphenols**: Enhanced formulations (curcumin for inflammation, EGCG for metabolism)

**NOT Recommended**:
- ‚ùå GH replacement (unless documented deficiency)
- ‚ùå Unproven peptides

---

### Age 65+ (Elderly, Healthspan Focus)

**Tier 1 (ABSOLUTE PRIORITY - Foundation for Independence)**:
- ‚úÖ **EXERCISE** (Grade A): MOST CRITICAL INTERVENTION at this age
  - **Resistance training**: 2-3 days/week (sarcopenia prevention, fall risk ‚Üì)
    - Priority: Squats, deadlifts, leg press (lower body strength = independence)
    - Target: Muscle mass +1.1 kg achievable even at 70+
  - **Aerobic**: 150 min/week minimum (cardiovascular health, cognitive preservation)
    - VO‚ÇÇmax improvement +16.3% even in 60-80 year-olds
  - **Balance training**: 2-3 days/week (ESSENTIAL - fall rate -23%, fractures -16%)
    - Tai Chi highly effective (43% fall reduction)
  - **Protein + Exercise**: 1.2-1.6 g/kg/day protein mandatory with training
    - Synergy: +87% greater muscle gain vs. standard protein
  - **Note**: Exercise at this age can REVERSE functional decline, not just slow it
- ‚úÖ **Senolytics**: D+Q 3-day pulse every 3 months (senescence burden higher)
- ‚úÖ **Mediterranean Diet**: Anti-inflammatory, cognitive protection
- ‚úÖ **Metformin**: If diabetic or prediabetic

**Tier 2 (Consider With Caution)**:
- üü° **Rapamycin**: 3-5 mg weekly (start low, elderly more sensitive)
  - Monitor infections closely
  - Greater benefit in females at this age (late-life treatment data)
  - **Must continue exercise** - rapamycin + exercise may be synergistic
- üü° **Exercise + Metformin + Rapamycin**: Triple approach for frailty prevention
- üü° **Thymosin Œ±1**: If recurrent infections (immune enhancement)

**Special Considerations**:
- Lower doses generally (age-related pharmacokinetic changes)
- More frequent monitoring (comorbidities, polypharmacy)
- **Functional outcomes PRIMARY** (grip strength, gait speed, chair stand, balance)
- Quality of life paramount
- **Exercise non-negotiable** - all other interventions supplementary

**NOT Recommended**:
- ‚ùå GH replacement (side effects > benefits, no functional improvement vs. exercise)
- ‚ùå Aggressive or experimental protocols
- ‚ùå Sedentary + pharmacology approach (exercise must be foundation)

---

## CLINICAL TRIAL LANDSCAPE: What's Coming (2025-2030)

### Definitive Trials to Watch

1. **TAME (Targeting Aging with Metformin)**: 2027-2028 results
   - 3,000 participants, age 65-79
   - Will definitively answer whether metformin extends healthspan in non-diabetics

2. **TRIAD (Test of Rapamycin In Aging Dogs)**: 2026-2028 results
   - 580 dogs, lifespan endpoint
   - Translational bridge between mice and humans

3. **Life Biosciences ER-100**: Q1 2026 Phase 1 initiation
   - First epigenetic reprogramming trial in humans
   - Vision restoration (glaucoma, NAION)

4. **Senolytic Trials** (Multiple): 2025-2027 results
   - Alzheimer's, osteoporosis, frailty, long COVID
   - Will establish efficacy beyond proof-of-concept

5. **Efruxifermin (FGF21 analog)**: 2025-2027 Phase 3 for NASH
   - May extend to metabolic syndrome and aging applications

---

## KEY TAKEAWAYS AND ACTIONABLE GUIDANCE

### What We Know (2025)

‚úÖ **PROVEN (Grade A)**:
- **EXERCISE**: ONLY intervention with robust human healthspan extension and mortality reduction
  - 30-40% mortality reduction (population studies)
  - Multi-system benefits: cardiovascular, metabolic, musculoskeletal, cognitive, immune
  - Extensive safety data, minimal contraindications
  - **Most cost-effective and impactful intervention available**

‚úÖ **Strong Animal Data + Emerging Human Evidence (Grade B)**:
- Rapamycin (10-15% lifespan extension in mice, emerging human safety data)
- Metformin (large human safety database, efficacy unclear, TAME trial pending 2027)
- Senolytics (human proof-of-concept established, efficacy trials ongoing)

üü° **Promising but Early Stage (Grade C)**:
- Reprogramming (revolutionary potential, first human trials 2026)
- Polyphenols (strong mechanistic rationale, bioavailability limitations)
- Select peptides (mixed evidence, safety concerns)

‚ùå **Not Recommended (Grade D)**:
- Most peptides (except specific deficiency states)
- Epitalon, GDF11, unproven "anti-aging" cocktails
- High-dose GH in healthy aging

### The Bottom Line

**Exercise is the ONLY intervention with proven human healthspan extension.** The most rational strategy for healthy aging:

**Foundation (Non-Negotiable)**:
1. **EXERCISE** (Grade A): Combined aerobic + resistance + balance
   - 150-300 min/week moderate-intensity aerobic
   - 2-3 days/week resistance training
   - Balance training (especially ‚â•65 years)
   - **Impact**: Greater than all pharmacological interventions combined
2. **Mediterranean Diet**: Anti-inflammatory, cardiovascular protection, cognitive benefits
3. **Sleep**: 7-9 hours/night (recovery, hormonal regulation)
4. **Stress Management**: Social connection, mindfulness, purpose

**Pharmacological Add-Ons (Under Medical Supervision)**:
- **Metformin** (Grade B): If metabolic risk factors present
- **Rapamycin** (Grade B): Consider if risk-tolerant, middle-age or elderly
- **Senolytics** (Grade B): Periodic pulses if inflammatory conditions
- **Exercise + Pharmacology**: Synergistic approach may be optimal

**Critical Insight**: **No pharmacological intervention can compensate for lack of exercise.** A sedentary person taking rapamycin + metformin will have worse outcomes than an exercising person taking nothing. Exercise MUST be the foundation.

**The next 5 years (2025-2030) will be transformative** with results from TAME, TRIAD, senolytic efficacy trials, and first reprogramming trials. Until then:
1. **Prioritize exercise** (Grade A evidence NOW)
2. Optimize diet, sleep, stress management
3. Carefully consider Grade B pharmacological interventions (under medical supervision)
4. Monitor this rapidly evolving field for emerging therapies

---

## APPENDIX: Clinical Resources

### Finding a Physician

**Physicians Prescribing Longevity Interventions**:
- Longevity/anti-aging medicine specialists
- Preventive medicine physicians
- Functional medicine practitioners
- Primary care (if knowledgeable and willing)

**Telemedicine options** available for longevity medicine consultations

### Cost Estimates (Annual, First Year)

| Intervention | Medication | Monitoring | Physician | Total |
|--------------|-----------|------------|-----------|-------|
| Metformin | $100-300 | $200-500 | $500-1,000 | $800-1,800 |
| Rapamycin | $1,200-3,600 | $700-1,900 | $800-2,000 | $2,700-7,500 |
| Senolytics (intermittent) | $100-500 | $200-500 | $500-1,000 | $800-2,000 |
| Polyphenols | $200-1,000 | None | None | $200-1,000 |
| Combination | $2,000-5,000 | $1,000-2,500 | $1,000-2,500 | $4,000-10,000 |

### References and Further Reading

**Key Papers**:
- Harrison et al. (2009): "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." Nature.
- Ocampo et al. (2016): "In vivo amelioration of age-associated hallmarks by partial reprogramming." Cell.
- Lu et al. (2020): "Reprogramming to recover youthful epigenetic information and restore vision." Nature.
- Hickson et al. (2019): "Senolytics decrease senescent cells in humans." EBioMedicine.

**Clinical Trial Registries**:
- ClinicalTrials.gov: Search "rapamycin aging", "metformin TAME", "senolytics"
- Dog Aging Project: TRIAD trial updates

**Organizations**:
- National Institute on Aging (NIA)
- American Federation for Aging Research (AFAR)
- SENS Research Foundation
- Longevity biotech companies (Altos Labs, Life Biosciences, Turn.bio, YouthBio)

---

**Document Status**: Current as of November 8, 2025
**Next Update**: Upon TAME trial results (2027) or major clinical trial publications
**Disclaimer**: This synthesis is for informational purposes only. Consult qualified healthcare providers before starting any intervention. Off-label use carries risks and should be undertaken with medical supervision and informed consent.

---

*End of Interventions Evidence Hierarchy Synthesis*
